Lexeo Therapeutics, Inc.
LXEODrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
How LXEO's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LX1001 | Phase 2 | Alzheimer Disease | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Lexeo Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Lexeo Therapeutics, Inc.'s (LXEO) pipeline across Phase 2. Its lead program is LX1001 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lexeo Therapeutics, Inc.'s next FDA catalyst?→
Lexeo Therapeutics, Inc.'s (LXEO) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LXEO biotech catalysts?→
Add LXEO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lexeo Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.